Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

Off-the-shelf CAR-T from stem cells? An early look at UCLA tech — licensed by Gilead
Endpoints
Thu, 02/21/19 - 10:47 pm
Tags:
CAR-T, Gilead Sciences, UCLA, stem cells
Medicare would cover CAR-T cell therapies under new CMS proposal
Marketwatch
Fri, 02/15/19 - 12:22 pm
Tags:
Medicare, CAR-T, cell therapy, CMS, Novartis, Kymriah, Gilead Sciences, Yescarta
It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial
Endpoints
Mon, 02/11/19 - 08:06 pm
Tags:
Gilead Sciences, NASH, selonsertib, clinical trials
Pharma companies clear the R&D decks in Q4
Pharmaforum
Mon, 02/11/19 - 12:20 pm
Tags:
R&D, GSK, Sanofi, Eli Lilly, Roche, Gilead Sciences
Why Gilead Sciences Stock Perked Up in January
Motley Fool
Sun, 02/10/19 - 01:51 pm
Tags:
Gilead Sciences, JPMHC 2019
Trump's HIV pledge comes as Gilead pumps cash into Truvada for PrEP
Fierce Pharma
Wed, 02/6/19 - 01:30 pm
Tags:
Gilead Sciences, HIV, Descovy, PrEP, Donald Trump
Gilead drops anti-BCMA CAR-T from Kite, takes $820M charge
Fierce Biotech
Tue, 02/5/19 - 11:50 am
Tags:
Gilead Sciences, Multiple Myeloma, Kite Pharma, anti-BCMA
Gilead executives predict patience—and some deal scouting—from new CEO Daniel O'Day
Fierce Pharma
Tue, 02/5/19 - 10:00 am
Tags:
Gilead Sciences, Daniel O'Day, M&A, Pharma CEOs
Gilead Misses Mark on Earnings as Daniel O'Day Prepares to Take Helm
Bloomberg
Mon, 02/4/19 - 05:53 pm
Tags:
Gilead Sciences, earnings
Gilead's hepatitis C generics are on their way, but Epclusa's getting TV ads anyway
Fierce Pharma
Mon, 02/4/19 - 11:40 am
Tags:
Gilead Sciences, hepatitis C, Epclusa, drug ads, television ads
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Fri, 02/1/19 - 12:00 am
Tags:
Novartis, Kymriah, CAR-T, UK, diffuse large B-cell lymphoma, Gilead Sciences
Based On Sales Forecasts For 2018 FDA Approved Drugs, Big Pharma Not Just Focused On Blockbusters
Forbes
Mon, 01/28/19 - 11:00 am
Tags:
Big Pharma, Pfizer, Merck, AstraZeneca, Gilead Sciences, Alexion, Vertex Pharmaceuticals
What’s up with all the buzz about Gilead’s PhIII NASH drug selonsertib?
Endpoints
Wed, 01/23/19 - 08:02 pm
Tags:
clinical trials, NASH, Gilead Sciences, selonsertib
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
Tags:
NASH, Allergan, Regeneron, Alnylam, AstraZeneca, Merck, Takeda, Gilead Sciences, Bristol-Myers Squibb, Intercept Pharmaceuticals
Gilead, Genentech join PhRMA
BioCentury
Fri, 01/18/19 - 12:03 am
Tags:
PhRMA, Genentech, Gilead Sciences
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
Tags:
NASH, Gilead Sciences, Merck, Roche, Novartis, Jecure Therapeutics, Pfizer, Celgene, Eli Lilly
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
Tags:
JPMHC 2019, M&A, Eli Lilly, Loxo Oncology, SAGE Therapeutics, Sanofi, Regeneron, Bristol-Myers Squibb, Celgene, Novartis, Gilead Sciences
7 Things to Expect for Gilead Sciences in 2019
Motley Fool
Tue, 01/8/19 - 09:12 am
Tags:
Gilead Sciences, JPMHC 2019, HIV, hepatitis C, M&A, Daniel O'Day
Gilead Inks $785 Million Deal With Yuhan for NASH Development
BioSpace
Mon, 01/7/19 - 11:16 am
Tags:
Gilead Sciences, NASH, South Korea, Yuhan
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
Sat, 01/5/19 - 01:34 pm
Tags:
M&A, Bristol-Myers Squibb, Celgene, Gilead Sciences, AbbVie, Amgen

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.